MEN1 and pancreatic neuroendocrine tumor: Promising results were also observed by the retrospective study of Ramundo et al., which confirmed the efficacy of octreotide LAR i.m. in tumor control and hormonal response in early-stage MEN1 duodenal–pancreatic NETs < 2 cm.